Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of diabetes increased FGF21 levels and both of the treatments could reduce its contents, however, glibenclamide was more effective than HESS.
|
31655149 |
2020 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis showed that FGF-21 level was associated with hepatic steatosis (OR 1.005, 95% CI 1.001-1.009) and F3/F4 (OR 0.993, 95% CI 0.989-0.998), while AFABP level (OR 1.001, 95% CI 1-1.002), body mass index (BMI) (OR 1.107, 95% CI 1.037-1.182) and presence of diabetes mellitus (OR 2.059, 95% CI 1.206-3.516) were associated with F3/F4.
|
30912255 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is closely linked with metabolic disorders including diabetes.
|
31205953 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is a potential diabetic drug, however, it has not been investigated whether FGF21 prevents neointima hyperplasia in DM.
|
31513948 |
2019 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher levels of FGF21 were expressed, particularly in patients with diabetes.
|
30959789 |
2019 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Female gender, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference (WC), body weight (BW), body mass index (BMI), body fat mass, fasting glucose, glycated hemoglobin level (HbA1c), triglyceride level (TG), urine albumin-to-creatinine ratio (UACR), insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), and FGF21 levels were higher, whereas high-density lipoprotein cholesterol level (HDL-C) and estimated glomerular filtration rate (eGFR) were lower in DM patients with MetS.
|
31582974 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease.
|
31798902 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, a member of the fibroblast growth factor (FGF) superfamily, FGF21 has proved tremendous efficacy in diseases like diabetes mellitus, obesity and insulin resistance (IR).
|
31333086 |
2019 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, we aim to examine whether FGF-21 regulates expression of intestinal SGLT1 in diabetes.
|
30551357 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.
|
31721467 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus.
|
30991048 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF-21) is an important regulator in glycolipid metabolism that is a promising drug candidate for treatment of diabetes and obesity.
|
31129207 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have indicated that fibroblast growth factor 21 (FGF21), an attractive and potential therapeutic treatment for DM, may exert diverse effects in the central nervous system.
|
30785085 |
2019 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes studies of the possible involvement of dietary methionine restriction in improving insulin resistance, glucose homeostasis, oxidative stress, lipid metabolism, the pentose phosphate pathway (PPP), and inflammation, with an emphasis on the fibroblast growth factor 21 and protein phosphatase 2A signals and autophagy in diabetes.
|
29603632 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed whether plasma concentrations of three known myokines [myonectin, myostatin, and fibroblast-derived growth factor 21 (FGF-21)] would be associated with direct and indirect indicators of insulin resistance (IR) in individuals who did not have a diagnosis of diabetes.
|
29445355 |
2018 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21-responsiveness machinery in adipose tissue.
|
30043445 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection.
|
29634312 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous studies have been conducted to establish and confirm whether FGF21 exerts beneficial effects on obesity and diabetes along with its complications.
|
29989062 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, FGF-21 was found to have anti-inflammatory effect, to our knowledge, the effect of FGF-21 on inflammatory state in diabetes has not been elucidated.
|
29414665 |
2018 |
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Circulating FGF21 level was independently associated with CIN (aOR: 4.66, 95% CI: 1.29-16.86, p = 0.019) and renal function decline (aHR: 7.98, 95% CI: 4.07-15.66, p < 0.001) whether diabetes was present or not.
|
30127382 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
During the past decade, there has been an enormous effort made to understand the physiological roles of FGF21 in regulating metabolism and to identify the mechanism for its potent pharmacological effects to reverse diabetes and obesity.
|
29727594 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, hepatic TTP posttranscriptionally regulates systemic insulin sensitivity in diabetes through liver-derived FGF21.
|
29997282 |
2018 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Metallothionein can modulate various stress-induced signaling pathways (mitogen-activated protein kinase, Wnt, nuclear factor-κB, phosphatidylinositol 3-kinase, sirtuin 1/AMP-activated protein kinase and fibroblast growth factor 21) to alleviate diabetes and diabetic complications.
|
29072367 |
2018 |
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This is in contrast to the anti-diabetic medication metformin and suggests that the treatment of obesity and diabetes with the combination of FGF21 and AMPK activators merits consideration.
|
28580278 |
2017 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG.
|
27611701 |
2017 |